Olufunmilayo Olopade, M.D.


Telephone number: 773-702-1632

Research Description

My research interests are diverse and include: treatment of breast cancer, especially in young or pregnant women; familial cancers; molecular genetics of cancer; cancer risk assessment and chemoprevention; breast cancer and minority populations and disparities in health outcomes. My clinical interests include breast cancer, cancer risk assessment, cancer prevention, and general hematology and medical oncology.

Selected Publications

Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2.
Catucci I, Casadei S, Ding YC, Volorio S, Ficarazzi F, Falanga A, Marchetti M, Tondini C, Franchi M, Adamson A, Mandell J, Walsh T, Olopade OI, Manoukian S, Radice P, Ricker C, Weitzel J, King MC, Peterlongo P, Neuhausen SL
(2016 Nov) Breast Cancer Res Treat. 2016 Nov;160(1):121-129. Epub 2016 Sep 13. 27624329

Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry.
Qian F, Feng Y, Zheng Y, Ogundiran TO, Ojengbede O, Zheng W, Blot W, Ambrosone CB, John EM, Bernstein L, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press MF, Nathanson KL, Hennis A, Nemesure B, Ambs S, Kolonel LN, Olopade OI, Haiman CA, Huo D
(2016 Oct) Hum Genet. 2016 Oct;135(10):1145-59. doi: 10.1007/s00439-016-1707-1. Epub 2016 Jul 5. 27380242 (Full Text)

Challenges and disparities in the application of personalized genomic medicine to populations with African ancestry.
Kessler MD, Yerges-Armstrong L, Taub MA, Shetty AC, Maloney K, Jeng LJ, Ruczinski I, Levin AM, Williams LK, Beaty TH, Mathias RA, Barnes KC, O'Connor TD
(2016 Oct) Nat Commun. 2016 Oct 11;7:12521. doi: 10.1038/ncomms12521. 27725664 (Full Text)

A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome.
Mathias RA et al.
(2016 Oct) Nat Commun. 2016 Oct 11;7:12522. doi: 10.1038/ncomms12522. 27725671 (Full Text)

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Lawrenson K et al.
(2016 Sep) Nat Commun. 2016 Sep 7;7:12675. doi: 10.1038/ncomms12675. 27601076 (Full Text)

Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer.
Huo D et al.
(2016 Sep) Hum Mol Genet. 2016 Sep 4. pii: ddw305. 27594435

Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients.
Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI
(2016 Aug) Oncotarget. 2016 Aug 23;7(34):55231-55248. doi: 10.18632/oncotarget.10485. 27409424

Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples.
Fackenthal JD et al.
(2016 Aug) J Med Genet. 2016 Aug;53(8):548-58. doi: 10.1136/jmedgenet-2015-103570. Epub 2016 Apr 8. 27060066

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Rugo HS et al.
(2016 Jul) N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749. 27406347

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.
Zeng C et al.
(2016 Jun) Breast Cancer Res. 2016 Jun 21;18(1):64. doi: 10.1186/s13058-016-0718-0. 27459855 (Full Text)

Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
Guindalini RS, Song A, Fackenthal JD, Olopade OI, Huo D
(2016 Jun) Cancer. 2016 Jun 15;122(12):1913-20. doi: 10.1002/cncr.29972. Epub 2016 Mar 15. 26992017 (Full Text)

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.
Couch FJ et al.
(2016 Apr) Nat Commun. 2016 Apr 27;7:11375. doi: 10.1038/ncomms11375. 27117709 (Full Text)

Building local capacity for genomics research in Africa: recommendations from analysis of publications in Sub-Saharan Africa from 2004 to 2013.
Adedokun BO, Olopade CO, Olopade OI
(2016) Glob Health Action. 2016 May 12;9:31026. doi: 10.3402/gha.v9.31026. eCollection 2016. 27178644 (Full Text)

Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Vigorito E et al.
(2016) PLoS One. 2016 Jul 27;11(7):e0158801. doi: 10.1371/journal.pone.0158801. eCollection 2016. 27463617 (Full Text)

Pilot study demonstrating potential association between breast cancer image-based risk phenotypes and genomic biomarkers.
Li H, Giger ML, Sun C, Ponsukcharoen U, Huo D, Lan L, Olopade OI, Jamieson AR, Brown JB, Di Rienzo A
(2014 Mar) Med Phys. 2014 Mar;41(3):031917. doi: 10.1118/1.4865811. 24593735 (Full Text)

Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis.
Harrell JC, Pfefferle AD, Zalles N, Prat A, Fan C, Khramtsov A, Olopade OI, Troester MA, Dudley AC, Perou CM
(2014 Jan) Clin Exp Metastasis. 2014 Jan;31(1):33-45. doi: 10.1007/s10585-013-9607-4. Epub 2013 Aug 22. 23975155 (Full Text)

Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution.
Oluwasola AO, Malaka D, Khramtsov AI, Ikpatt OF, Odetunde A, Adeyanju OO, Sveen WE, Falusi AG, Huo D, Olopade OI
(2013 Dec) Ann Diagn Pathol. 2013 Dec;17(6):526-30. doi: 10.1016/j.anndiagpath.2013.07.003. Epub 2013 Oct 2. 24095629

International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers.
Semple J, Metcalfe KA, Lynch HT, Kim-Sing C, Senter L, Pal T, Ainsworth P, Lubinski J, Tung N, Eng C, Gilchrist D, Blum J, Neuhausen SL, Singer CF, Ghadirian P, Sun P, Narod SA
(2013 Nov) Ann Surg Oncol. 2013 Nov;20(12):3817-22. doi: 10.1245/s10434-013-3040-4. Epub 2013 Jun 6. 23740344 (Full Text)

The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation.
Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P, Neuhausen SL, Weitzel J, Singer CF, Olopade OI, Saal H, Lyonnet DS, Foulkes WD, Kim-Sing C, Manoukian S, Zakalik D, Armel S, Senter L, Eng C, Grunfeld E, Chiarelli AM, Poll A, Sun P, Narod SA
(2013 Nov) Breast Cancer Res Treat. 2013 Nov;142(1):177-85. doi: 10.1007/s10549-013-2729-1. Epub 2013 Oct 18. 24136669 (Full Text)

Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases.
Yamaguchi K, Schacht D, Newstead GM, Bradbury AR, Verp MS, Olopade OI, Abe H
(2013 Nov) AJR Am J Roentgenol. 2013 Nov;201(5):1155-63. doi: 10.2214/AJR.12.9707. 24147491

Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study.
Hou N, Ogundiran T, Ojengbede O, Morhason-Bello I, Zheng Y, Fackenthal J, Adebamowo C, Anetor I, Akinleye S, Olopade OI, Huo D
(2013 Sep) Ann Epidemiol. 2013 Sep;23(9):551-7. doi: 10.1016/j.annepidem.2013.06.008. Epub 2013 Jul 20. 23880155 (Full Text)

Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density.
Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D
(2013 Sep) J Natl Cancer Inst. 2013 Sep 18;105(18):1365-72. doi: 10.1093/jnci/djt207. Epub 2013 Sep 3. 24003037 (Full Text)

Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers.
Zheng Y, Ogundiran TO, Falusi AG, Nathanson KL, John EM, Hennis AJ, Ambs S, Domchek SM, Rebbeck TR, Simon MS, Nemesure B, Wu SY, Leske MC, Odetunde A, Niu Q, Zhang J, Afolabi C, Gamazon ER, Cox NJ, Olopade CO, Olopade OI, Huo D
(2013 Jul) Carcinogenesis. 2013 Jul;34(7):1520-8. doi: 10.1093/carcin/bgt090. Epub 2013 Mar 8. 23475944 (Full Text)

Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study.
Arowolo OA, Njiaju UO, Ogundiran TO, Abidoye O, Lawal OO, Obajimi M, Adetiloye AV, Im HK, Akinkuolie AA, Oluwasola A, Adelusola K, Kayode AA, Agbakwuru AE, Oduntan H, Babalola CP, Fleming G, Olopade OC, Falusi AG, Durosinmi MA, Olopade OI
(2013 Sep) Breast J. 2013 Sep-Oct;19(5):470-7. doi: 10.1111/tbj.12149. Epub 2013 Jul 19. 23865786 (Full Text)

MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H
(2013) Nat Commun. 2013;4:1393. doi: 10.1038/ncomms2393. 23340433 (Full Text)

Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer.
Bhatta SS, Hou N, Moton ZN, Polite BN, Fleming GF, Olopade OI, Huo D, Hong S
(2013) Springerplus. 2013 Jul 30;2:356. doi: 10.1186/2193-1801-2-356. eCollection 2013. 23961419 (Full Text)

Comprehensive molecular portraits of human breast tumours.

(2012 Oct) Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23. 23000897 (Full Text)

High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients.
Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos F, Burrill DR, Niu Q, Huo D, Sveen WE, Ogundiran T, Adebamowo C, Odetunde A, Falusi AG, Olopade OI
(2012 Sep) Int J Cancer. 2012 Sep 1;131(5):1114-23. doi: 10.1002/ijc.27326. Epub 2012 Jan 27. 22034289

Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.
Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling RV, Olugbile S, Polite BN, Olopade OI
(2012 Jan) Clin Cancer Res. 2012 Jan 15;18(2):350-9. doi: 10.1158/1078-0432.CCR-11-1397. Epub 2011 Nov 23. 22114137 (Full Text)

Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI
(2009 Sep) J Clin Oncol. 2009 Sep 20;27(27):4515-21. doi: 10.1200/JCO.2008.19.6873. Epub 2009 Aug 24. 19704069 (Full Text)

BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI
(2005 Dec) Cancer Res. 2005 Dec 1;65(23):10692-9. 16322213

Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI
(2005 Oct) JAMA. 2005 Oct 19;294(15):1925-33. 16234499

MYC is amplified in BRCA1-associated breast cancers.
Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Ridderstrale KK, Anderson KN, Wei MJ, Adams AJ, Hagos FG, Sveen L, Lynch HT, Weber BL, Olopade OI
(2004 Jan) Clin Cancer Res. 2004 Jan 15;10(2):499-507. 14760071

Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI
(2002 Mar) Cancer Res. 2002 Mar 1;62(5):1481-8.